Study of Chediak-Higashi Syndrome

Conditions

• Chediak-Higashi Syndrome

Eligibility Criteria

Sex

ALL

Age

1 Month - 70 Years

Healthy Volunteers

Not accepted

Study Details

Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disorder characterized in its classical form by oculocutaneous albinism, a bleeding diathesis, recurrent infection due to abnormal neutrophil and natural killer cell function, and eventual progression to a lymphohistiocytic infiltration known as the accelerated phase . Death often occurs within the first decade as a result of infection or the development of the accelerated phase; bone marrow transplantation is curative except for the late occurrence of neurological deterioration. The basic defect is unknown, although it probably involves abnormal fusion or trafficking of intracellular vesicles. Patients with classical CHS have their disease due to mutations in the LYST gene, but mildly affected individuals have been reported whose genetic defect has not been defined. It is likely that these variants of CHS have abnormalities in proteins involved in the pathways responsible for vesicle fusion. Since the full clinical spectrum of CHS and its variants has not been characterized, and the underlying defects remain enigmatic, we plan to evaluate this group of patients clinically, biochemically, and molecularly, and perform cell biological studies on their fibroblasts, melanocytes, and transformed lymphoblasts. Routine admissions will be 5 days and may occur every two years, or required by changes in clinical symptomatology.

Key Dates

Start date

Sep 10, 2002

Status verified

May 2026

Study Design

Enrollment

60 participants (estimated)

Arms

• Arm: Chediak-Higashi Syndrome
  Confirmed or suspected patients with Chediak-Higashi Syndrome.

Primary Outcome Measure

Delineate the clinical and laboratory findings of CHS and its variants. [ Time Frame: 4-5 days every 1-2 years ]

Central Contacts

• Wendy J Introne, M.D.
  (301) 451-8879
  [email protected]

Locations (1)

Find similar trials in Bethesda, MD